Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019-2021) : A Population-Based Epidemiological Study
Domínguez, Ángela (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Soldevila, Núria (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Toledo, Diana (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Parrón, Ignacio (Agència de Salut Pública de Catalunya)
Millet, Joan Pau (Institut d'Investigació Biomèdica Sant Pau)
Barrabeig, Irene (Agència de Salut Pública de Catalunya)
Godoy, Pere (Institut de Recerca Biomédica de Lleida (IRBLleida))
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019-2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80. 6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14. 20; 95% CI 5. 22-38. 66) and exposure <6 h/day (aOR 7. 32, 95% CI 2. 48-21. 64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0. 22, 95% CI 0. 08-0. 64) and bacillus Calmette-Guerin vaccination (aOR 0. 38, 95% CI 0. 16-0. 90). Crucial to LTBI treatment prescription is information on the contact's duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels.
Grants:	Instituto de Salud Carlos III PI18/01751
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Contact tracing ; Latent TB infection ; Prescription ; Prevention ; Treatment ; Tuberculosis
Published in:	Vaccines (Basel), Vol. 11 Núm. 12 (december 2023) , p. 1800, ISSN 2076-393X

DOI: 10.3390/vaccines11121800
PMID: 38140204

12 p, 823.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles